‘Pharma Bro’ Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks
The Federal Trade Commission and seven states say Shkreli should be held in contempt
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
